Osso VR Raises $66 Million

Osso VR, a validated virtual reality (VR) surgical training and assessment platform, today announced that it has secured $66 million in Series C funding led by Oak HC/FT. The round also includes participation from Signalfire, GSR Ventures, Tiger Global Management and Kaiser Permanente Ventures.

The capital will be used to accelerate Osso VR’s initiative to broaden access to surgical education for all healthcare professionals and continue the investment in hiring top-tier talent to bring high-fidelity surgical training experiences to additional specialty areas.
Osso VR produces on-demand, immersive modules that allow surgical teams to train independently or collaboratively in a virtual environment before ever stepping foot into a real operating room. Medical device companies also use Osso VR to introduce technology digitally, addressing many challenges of traditional educational pathways ⁠such as conflicting physician schedules, remote staff, and costly travel. With Osso VR, more surgeons can practice utilizing complex medical technologies to more rapidly offer their patients access to the best procedures with optimal outcomes.
“Oak HC/FT is continuously seeking new opportunities to support innovative companies impacting the healthcare industry in a meaningful way,” said Vig Chandramouli, Partner at Oak HC/FT. “Osso VR is well positioned to become the gold standard for all surgical training and continuing education, and we’re thrilled to work alongside this impassioned and committed team.”
Osso VR currently partners with leading global medical device companies, including Johnson & Johnson, Stryker, Zimmer Biomet, and Smith + Nephew. The company’s modules cover multiple specialty areas, such as orthopedics, spine, interventional cardiology, and general surgery, amongst others.
“The future at Osso VR is incredibly bright. Each step of the way, we’ve stayed true to our mission to democratize healthcare and seen the results that our platform brings to surgical training and  assessment,” said Justin Barad, MD, CEO and Co-Founder of Osso VR. “This round of investment supports the next step of our journey to provide access to all healthcare professionals. I couldn’t be more excited to take this next step with such a talented, passionate team.”
The company has more than 150 employees and plans to grow exponentially over the next year. Osso VR designs and develops all virtual experiences in-house and has hired talent across an array of industries, including healthcare, technology, movies and gaming. The company boasts the largest team of medical illustrators in the world.
The funding news comes on the heels of Osso VR winning the prestigious SXSW Innovation Award for VR, AR, and MR. The company is also exhibiting at the AAOS 2022 Annual Meeting this week in Chicago, Ill.
SourceOsso VR

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.